{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:52Z","timestamp":1792057732401,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xops.2026.101340","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:33:49Z","timestamp":1785281629000},"page":"101340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["GOLDEN: Efficacy and Safety of Complement Factor B Antisense, Sefaxersen, in Geographic Atrophy due to Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-7892","authenticated-orcid":false,"given":"Glenn J.","family":"Jaffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9927-3233","authenticated-orcid":false,"given":"Michael L.","family":"McCaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-8365","authenticated-orcid":false,"given":"Terrance D.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashely","family":"Frazer-Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich F.O.","family":"Luhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Cukras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lomax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Fauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary T.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101340_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2026.101340_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.molimm.2016.11.016","article-title":"The complement system in age-related macular degeneration: a review of rare genetic variants and implications for personalized treatment","volume":"84","author":"Geerlings","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.xops.2026.101340_bib3","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.1073\/pnas.1019338108","article-title":"Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk","volume":"108","author":"Heurich","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xops.2026.101340_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng1750","article-title":"Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration","volume":"38","author":"Gold","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.xops.2026.101340_bib5","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1073\/pnas.0812584106","article-title":"Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B","volume":"106","author":"Montes","year":"2009","journal-title":"Proc Nat Acad Sci U S A"},{"key":"10.1016\/j.xops.2026.101340_bib6","first-page":"561","article-title":"Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide","volume":"23","author":"Grossman","year":"2017","journal-title":"Mol Vis"},{"key":"10.1016\/j.xops.2026.101340_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.1997.d01-890.x","article-title":"Extrahepatic complement biosynthesis: where, when and why?","volume":"107","author":"Morgan","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.xops.2026.101340_bib8","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.12-9587","article-title":"Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration","volume":"53","author":"Loyet","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101340_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/srep26568","article-title":"A novel complotype combination associates with age-related macular degeneration and high complement activation levels in vivo","volume":"6","author":"Paun","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2026.101340_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/32b9bc31-ed6d-4d31-9ce0-480407017bad","article-title":"Systemic complement activation in age-related macular degeneration","volume":"3","author":"Scholl","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101340_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093459","article-title":"Impact of the common genetic associations of age-related macular degeneration upon systemic complement component C3d levels","volume":"9","author":"Ristau","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101340_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.11.005","article-title":"Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy","volume":"45","author":"Whitmore","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2026.101340_bib13","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101340_bib14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101340_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.152876","article-title":"Inhibiting the alternative pathway of complement by reducing systemic complement factor B: randomized, double-blind, placebo-controlled phase 1 studies with sefaxersen","volume":"230","author":"McCaleb","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.xops.2026.101340_bib16","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.kint.2025.11.017","article-title":"A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B for treatment of IgA nephropathy","volume":"109","author":"Barbour","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.xops.2026.101340_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101340_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100383","article-title":"Gradeability and reproducibility of geographic atrophy measurements in GATHER-1, a phase II\/III randomized interventional trial","volume":"4","author":"Li","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2026.101340_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2018.06.001","article-title":"Complement analysis in the era of targeted therapeutics","volume":"102","author":"Proh\u00e1szka","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1016\/j.xops.2026.101340_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1180833","article-title":"In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway","volume":"14","author":"Ispasanie","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.xops.2026.101340_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.xops.2026.101340_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/imr.13160","article-title":"Alternative pathway amplification and infections","volume":"313","author":"Shaughnessy","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.xops.2026.101340_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.xops.2026.101340_bib24","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xops.2026.101340_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/nat.2013.0443","article-title":"Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals","volume":"23","author":"Hung","year":"2013","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.xops.2026.101340_bib26","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.xops.2026.101340_bib27","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xops.2026.101340_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2006.09.016","article-title":"The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials","volume":"114","author":"Sunness","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101340_bib29","series-title":"Novartis. Fabhalta (iptacopan) prescribing information","year":"2024"},{"key":"10.1016\/j.xops.2026.101340_bib30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular atrophy in the HARBOR study for neovascular age-related macular degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101340_bib31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 Inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101340_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.exer.2014.07.021","article-title":"Polyethylene glycol induced mouse model of retinal degeneration","volume":"127","author":"Lyzogubov","year":"2014","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2026.101340_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2494775","article-title":"PEGylation technology: addressing concerns, moving forward","volume":"32","author":"Simberg","year":"2025","journal-title":"Drug Deliv"},{"key":"10.1016\/j.xops.2026.101340_bib34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41433-024-03463-w","article-title":"Gene therapy for geographic atrophy in age-related macular degeneration: current insights","volume":"39","author":"Jamil","year":"2025","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2026.101340_bib35","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101340_bib36","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.3390\/jcm12082870","article-title":"Bruch\u2019s membrane: a key consideration with complement-based therapies for age-related macular degeneration","volume":"12","author":"Hammadi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2026.101340_bib37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/imr.13145","article-title":"Age-related macular degeneration: a disease of extracellular complement amplification","volume":"313","author":"de Jong","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.xops.2026.101340_bib38","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2013.01.004","article-title":"Age-related macular degeneration and modification of systemic complement factor H production through liver transplantation","volume":"120","author":"Khandhadia","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101340_bib39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/imr.13149","article-title":"Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway","volume":"313","author":"Dreismann","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.xops.2026.101340_bib40","year":"2025","journal-title":"ClinicalTrials.gov identifier: NCT07215390"},{"key":"10.1016\/j.xops.2026.101340_bib41","article-title":"A study investigating subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in adult participants with geographic atrophy (SIENNA)","year":"2025","journal-title":"ClinicalTrials.gov identifier: NCT06541704"},{"key":"10.1016\/j.xops.2026.101340_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ajo.2025.04.016","article-title":"Pegcetacoplan treatment for geographic atrophy in age-related macular degeneration over 36 months: data from OAKS, DERBY, and GALE","volume":"276","author":"Wykoff","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101340_bib43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/08164622.2024.2361752","article-title":"Emerging treatments for geographic atrophy and the impact on clinical management of age-related macular degeneration","volume":"107","author":"Abbott","year":"2024","journal-title":"Clin Exp Optom"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:23:42Z","timestamp":1792056222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526002782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666914526002782"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101340","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GOLDEN: Efficacy and Safety of Complement Factor B Antisense, Sefaxersen, in Geographic Atrophy due to Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101340"}}